Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Gene2Cure Foundation y Viralgen colaboran para impulsar una cartera de programas de terapia génica

      • USA - English
      • USA - English
      Viralgen logo

      News provided by

      Viralgen

      Nov 17, 2026, 23:24 ET

      Share this article

      Share this article


      -Gene2Cure Foundation y Viralgen colaboran para impulsar una cartera de programas de terapia génica destinados a enfermedades genéticas raras y ultrarraras

      La colaboración aúna las capacidades de desarrollo de la cartera de Gene2Cure y la plataforma patentada Aava™ de Viralgen, con el fin de favorecer el avance eficiente hacia la fase clínica de programas dirigidos a enfermedades genéticas raras y ultrarraras

      DONOSTIA / SAN SEBASTIÁN, España, 18 de noviembre de 2026 /PRNewswire/ -- Gene2Cure Foundation, una organización sin ánimo de lucro dedicada a impulsar el desarrollo y la traslación clínica de terapias génicas innovadoras para afecciones genéticas pediátricas raras y ultrarraras, junto con Viralgen, una destacada organización de desarrollo y fabricación por contrato (CDMO) especializada en la producción de terapias génicas basadas en virus adenoasociados (AAV) han anunciado hoy una colaboración para apoyar la fabricación de una cartera de programas de terapia génica en fase de investigación destinados a enfermedades genéticas raras y ultrarraras.

      Continue Reading
      Viralgen scientist
      Viralgen scientist

      En virtud del acuerdo, Gene2Cure utilizará la plataforma de fabricación patentada Aava™ de Viralgen para impulsar el avance de su cartera de terapias génicas. Inicialmente, la colaboración respaldará programas centrados en el síndrome PUS3, el síndrome de Smith-Lemli-Opitz y GAND, afecciones genéticas raras para las que aún existen importantes necesidades médicas no cubiertas.

      Viralgen prestará servicios de fabricación AAV adaptados a los requisitos y a la fase de cada programa, lo que incluye la producción de material para estudios toxicológicos y/o para uso clínico. Su plataforma Aava™ está diseñada para ofrecer una vía de fabricación escalable, aplicable a diversos serotipos de AAV, y para facilitar el progreso de los programas desde la etapa preclínica hasta el desarrollo clínico y su posterior comercialización.

      "Nos entusiasma colaborar con Viralgen para acercar terapias génicas experimentales que podrían salvar vidas a niños que padecen afecciones genéticas incurables", afirmó el profesor Leszek Lisowski, cofundador y presidente de la Gene2Cure Foundation. "Al ayudarnos a desarrollar terapias de manera más rápida y rentable, esta colaboración brinda esperanza a los niños afectados y a sus familias".

      "La colaboración es fundamental para hacer avanzar posibles terapias génicas para enfermedades raras, especialmente en áreas donde las rutas de desarrollo pueden ser complejas", afirmó Jimmy Vanhove, consejero delegado de Viralgen. "Nos entusiasma trabajar con Gene2Cure y apoyar el avance de sus programas a través de etapas clave de desarrollo preclínico y clínico, facilitando el acceso a nuestra plataforma de fabricación Aava™".

      Acerca de Gene2Cure Foundation

      Gene2Cure Foundation es una organización sin ánimo de lucro con sede en los Estados Unidos (clasificada bajo la sección 501(c)(3)) dedicada a impulsar terapias génicas potencialmente capaces de salvar vidas para niños afectados por enfermedades genéticas raras y ultrarraras. Con un alcance internacional, la fundación reúne experiencia en los ámbitos científico, clínico y de fabricación para transformar investigaciones prometedoras en tratamientos experimentales destinados a afecciones que cuentan con pocas o ninguna opción terapéutica. Gracias al apoyo de donaciones filantrópicas, Gene2Cure se centra en desarrollar terapias seguras y eficaces de la manera más rápida y rentable posible, asegurando que cada contribución contribuya a mejorar la vida de los niños afectados y sus familias. Obtenga más información en gene2cure.com y siga a Gene2Cure en LinkedIn, Instagram, Facebook y YouTube.

      Acerca de Viralgen

      Viralgen es una organización líder en desarrollo y fabricación por contrato (CDMO) que se especializa exclusivamente en terapias génicas basadas en virus adenoasociados (AAV). Fundada en 2017 como filial de AskBio Inc., dentro del grupo Bayer AG, Viralgen ofrece un soporte integral que abarca desde las etapas iniciales de desarrollo hasta la fabricación comercial a gran escala. Gracias a su línea celular en suspensión patentada, Pro10™, y a su plataforma de fabricación, Aava™, Viralgen permite una producción escalable y de alto rendimiento para diversos serotipos de AAV. Con sede en San Sebastián (España), sus instalaciones de vanguardia cuentan con tres salas certificadas bajo normas cGMP, cada una con una capacidad de 2.000 litros, y están avaladas por la AEMPS. La compañía integra una amplia gama de servicios, que incluyen la producción de plásmidos, la optimización de procesos, el llenado y acabado, así como pruebas de control de calidad realizadas internamente. Con más de 2.000 lotes de AAV producidos, Viralgen proporciona soluciones fiables y eficientes que contribuyen a hacer llegar terapias génicas transformadoras a los pacientes con mayor rapidez y consistencia. Más información en viralgen.com y siga a Viralgen en LinkedIn.

      Modal title

      Also from this source

      Gene2Cure Foundation and Viralgen collaborate to advance a portfolio of gene therapy programs for rare and ultra-rare genetic conditions

      Gene2Cure Foundation and Viralgen collaborate to advance a portfolio of gene therapy programs for rare and ultra-rare genetic conditions

      Gene2Cure Foundation, a non-profit organization dedicated to advancing the development and clinical translation of innovative gene therapies for rare ...

      Gene2Cure Foundation and Viralgen collaborate to advance a portfolio of gene therapy programs for rare and ultra-rare genetic conditions

      Gene2Cure Foundation and Viralgen collaborate to advance a portfolio of gene therapy programs for rare and ultra-rare genetic conditions

      Gene2Cure Foundation, a non-profit organization dedicated to advancing the development and clinical translation of innovative gene therapies for rare ...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Health Care & Hospitals

      Health Care & Hospitals

      Not For Profit

      Not For Profit

      Licensing

      Licensing

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.